AU · rank #18 · 2026-09-09
EOLS
NASDAQ · $614M (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.797 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.04 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 4 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.153 |
| Analyst upside Consensus target $15.00 | +68.9% |
| Momentum acceleration 3-month minus 12-month momentum. | +31.36% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.57 |
| Gross margin TTM | +66.4% |
| 52w high | $9.31 |
| Market cap (USD) | $614M |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Evolus Inc. is a specialty beauty company focused on the cash-pay aesthetics market, primarily commercializing its Jeuveau neuromodulator and Evolysse dermal fillers [RECENT_DEVELOPMENTS, BUSINESS_STATUS].
Rationale
A strong Q2 2026 earnings beat and raised full-year revenue outlook of $330–$337M validate the model's signal of 100% analyst revision agreement and substantial upside potential [RECENT_DEVELOPMENTS, FINANCIAL_NOTES].
Material risks
- 1Extreme product concentration on only two primary aesthetic offerings, Jeuveau and Evolysse, making the company highly vulnerable to safety, regulatory, or localized competitive shocks [TOP_RISKS].
- 2Exposure to discretionary, out-of-pocket consumer spending, which is highly sensitive to macroeconomic downturns that could depress non-reimbursed aesthetic procedures [TOP_RISKS].
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.